Financial Performance and Growth - Royalty Pharma is on track to deliver $4.7 billion+ in top-line revenue in 2030, representing a 10%+ CAGR from 2020 to 2030[10, 353] - The company has delivered consistent mid-teens ROIC (Return on Invested Capital)[11, 354] - Royalty Pharma's 2030 top- and bottom-line outlook is >10% above analyst consensus[11, 354] - The company's goal is at least mid-teens TSR (Total Shareholder Return) over the next 5 years[11, 354] - Portfolio Receipts are expected to reach approximately $3.1 billion in 2025, based on guidance provided on August 6, 2025, plus expected contribution from the Imdelltra royalty acquisition announced on August 25, 2025[21] Market Dynamics and Strategy - The average annual royalty market size was $6 billion from 2020-2024, representing ~130% growth from the prior 5-year period[10, 353] - Royalty Pharma has a market share of ~50% from 2020 to present, which is ~4-fold higher than the next largest competitor, with >70% share of transactions ≥$500 million[120, 191] - Repeat partners have driven ~30% of announced transaction value since 2020[120, 191] - 87% of biopharma executives would consider royalties as part of their capital raising plans over the next 3 years[110] - Since 2012, Royalty Pharma has deployed approximately $27 billion of capital, with 65% allocated to approved products and 35% to development-stage therapies[46, 49]

MZE782 Phase 1 Trial Results - MZE782 demonstrated an excellent safety profile with no serious adverse events observed[18] - MZE782 exhibited linear pharmacokinetics (PK) across single doses ranging from 30 mg to 960 mg, with a half-life of approximately 11 hours[18, 32] - The trial showed up to a 42-fold increase in urinary phenylalanine (Phe) excretion and a 68-fold increase in urinary glutamine (Gln) excretion at Day 7[18] - MZE782 induced a dose-dependent initial estimated glomerular filtration rate (eGFR) dip, similar to SGLT2 inhibitors[18] Planned Phase 2 Trials in 2026 - The company plans to initiate Phase 2 trials for both Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) in 2026[18] - The PKU Phase 2 trial aims to demonstrate proof-of-concept (PoC) with plasma Phe reduction as the endpoint[56] - The CKD Phase 2 trial will focus on demonstrating PoC with proteinuria reduction as the primary endpoint[56] MZE782 Therapeutic Potential - MZE782 aims to deliver potential best-in-class plasma phenylalanine (Phe) reduction with a good safety profile for PKU patients[17] - MZE782 could be a new mechanism of action (MoA) to address CKD patients with inadequate response to current therapies, including SGLT2 inhibitors[56] Company Financial Position - The company has a strong cash position with an expected runway into 2028[12]

Financial Performance - For FY25, Net Revenue increased by 38% to R53 billion, compared to R38 billion in FY24[20] - Group Adjusted EBITDA for FY25 increased by 33% to R922 million, compared to R691 million in FY24[20] - Adjusted earnings per share increased by 187% to R229 in FY25, compared to R080 in FY24[20] - For Q4 FY25, Net Revenue increased by 47% to R15 billion, compared to R10 billion in Q4 FY24[35] - Group Adjusted EBITDA for Q4 FY25 increased by 61% to R306 million, compared to R190 million in Q4 FY24[35] - Adjusted earnings per share for Q4 FY25 increased by 211% to R099, compared to R032 in Q4 FY24[35] Strategic Initiatives - The company acquired Adumo for R17 billion, Recharger for R507 million, and announced the acquisition of Bank Zero for R11 billion[26] - The company exited non-core asset MobiKwik for R290 million, using proceeds to reduce gross debt[26] FY26 Guidance - The company expects FY26 Net Revenue to be between R64 billion and R69 billion, representing a YoY growth of 21%-30%[110] - The company expects FY26 Group Adjusted EBITDA to be between R125 billion and R145 billion, representing a YoY growth of 36%-57%[110] - The company expects FY26 Adjusted EPS to be greater than R460, representing a YoY growth of over 100%[110]

Welcome September 11, 2025 Agenda Arnaud Pieton ChiefExecutive Officer BrunoVibert ChiefFinancial Officer Q&A Deal strategic rationale AM&C business overview Financials & value creation Benjamin Lechuga Chief Strategy & Sustainability Officer A Company in Motion Acquisition of Ecovyst's Advanced Materials & Catalysts business ("AM&C") Today's speakers Arnaud Pieton Chief Executive Officer Benjamin Lechuga Chief Strategy & Sustainability Officer Bruno Vibert ChiefFinancial Officer 2 Acquisition of Ecovyst's ...

SPK-30 Strategy Overview - Spark's SPK-30 strategy aims to help New Zealand win big in a digital world, focusing on better networks and customer experiences[52] - The strategy builds on competitive advantages, including market leadership in mobile and broadband, a reliable mobile network, and a trusted brand[46] - Key strategic choices involve leading in core connectivity and simplifying/optimizing beyond the core[53] Financial Performance and Targets - In FY25, Spark's ROIC was 8.7%, outperforming most global peers[46] - The DC Co transaction values the data center business at $705 million, representing an EV/EBITDA multiple of 30.8x based on FY25 pro-forma EBITDA[67] - Spark expects to receive initial cash proceeds of ~$486 million at completion, with additional deferred cash proceeds of up to ~$98 million contingent on performance-based objectives by the end of CY27[67] - The company targets annualised savings of $150 million-$180 million by FY30 from a FY24 baseline[212, 213] - Spark aims for a low single-digit CAGR in EBITDAI from FY25-FY30 and a mid-single-digit CAGR in free cash flow from FY25-FY30[212, 213] Market Position and Growth Areas - Spark is the 1 mobile provider with 41.4% market share[92] - Spark is the 1 broadband provider with ~32% market share[102] - Wireless Broadband (WBB) accounts for 32% of Spark's broadband base[102] - 4G network reaches 99% of New Zealanders, and >50% of the population is reached by 5G network[114, 147]

Eisai's Strengths in Orexin Platform Highlight of E2086 Oral Presentation at World Sleep 2025 September 11, 2025 Eisai Co., Ltd. Katsutoshi Ido, Ph.D. Chief Scientific Officer Orexin: A Key Regulator of Sleep-Wakefulness Orexin receptor antagonist Dayvigo Orexin Sleep Center Arousal Center Suppression Dayvigo Suppressing excessive orexin signaling at night Inhibition Sleep Orexin receptor agonist E2086 2 Sleep Center Arousal Center Orexin Suppression E2086 Enhancement of daytime orexin signaling Enhancement ...

Financial Performance - Revenue for FY25 reached $1063 million, compared to $1100 million in FY24[19, 32] - Adjusted EBITDA for FY25 was $365 million, a significant increase from $243 million in FY24[19, 38] - Earnings per share increased from $009 in FY24 to $030 in FY25[19, 35] - Gross margin improved from 117% in FY24 to 125% in FY25[34] - Net income increased substantially from $46 million in FY24 to $151 million in FY25[37] Q4 FY25 Performance - Revenue for Q4 FY25 was $228 million, slightly lower than $237 million in Q4 FY24[21] - Cost of revenue decreased from $210 million in Q4 FY24 to $192 million in Q4 FY25[23] - Gross margin percentage increased from 114% in Q4 FY24 to 158% in Q4 FY25[25] - Earnings per share increased from $005 in Q4 FY24 to $011 in Q4 FY25[27] - Net income increased from $25 million in Q4 FY24 to $58 million in Q4 FY25[28] - Adjusted EBITDA increased significantly from $21 million in Q4 FY24 to $122 million in Q4 FY25[30] Business Overview - The company's exclusive distribution and licensing agreements drive annual sales exceeding $375 million[40] - Direct-to-consumer (DTC) sales contribute 37% of the company's net revenue[64]

BANK OF AMERICA SECURITIES GLOBAL REAL ESTATE CONFERENCE September 10, 2025 DISCLAIMER This presentation includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and are intended to be covered by the safe harbor provisions thereof. All statements, other than statements of historical facts, included in this presentation that address activities, events or developments that we expect, believe or anticipate will ...

SERENITY At-Home Trial Overview - The SERENITY At-Home trial evaluated the safety and tolerability of BXCL501 (120 mcg) for agitation associated with bipolar disorder or schizophrenia in the at-home setting[2, 27, 28] - The trial design was a double-blind, placebo-controlled study with a 1:1 randomization to BXCL501 (N=100) or placebo (N=100) over a 12-week period[27] - The study included patients aged 18-75 years with bipolar I or II disorder, schizophrenia, schizoaffective, or schizophreniform disorder on a stable psychotropic regimen[30] Key Results - The trial collected data from 2,628 agitation episodes in 215 patients, with 2,437 episodes treated in 208 patients[21, 22, 36] - 168 (81%) of treated patients completed the full 12-week study, with an average of 117 agitation episodes recorded per treated patient[36] - No drug-related serious adverse events (SAEs), falls, or syncopes were reported in the BXCL501 arm[23, 37] - The adverse event profile was consistent with the approved IGALMI® label and other clinical trials in institutional settings[23, 37] - Somnolence was the most common treatment-emergent adverse event (TEAE) in the BXCL501 group, occurring in 23 (225%) of patients after the first dose and 161 (139%) of all doses[38] Clinical Benefit - BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2 hours across 2,433 treated episodes (P<005)[41] - Complete resolution of agitation was significantly higher with BXCL501 compared to placebo across agitation episode severity (P<0001)[41] - For fully resolved episodes by baseline severity, BXCL501 showed higher percentages than placebo across mild, moderate, and severe agitation episodes[43] Next Steps - BioXcel Therapeutics plans to prepare and submit an sNDA (supplemental New Drug Application) in Q1 2026 for label expansion of IGALMI®[12, 23]

Precious Metals Summit, Beaver Creek September 9-12, 2025 TSX, NYSE AMERICAN: NG | NOVAGOLD.COM CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING STATEMENTS This presentation includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable securities legislation, including the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements include future-oriented financial information or fina ...